JSM Welcomes Dr. Fabio Castiglione as Associate Editor
Flibanserin and Alcohol: No Additional Adverse Events
We are delighted to announce that Fabio Castiglione MD, PhD, FEBU, FECSM, will be joining the Journal of Sexual Medicine as an Associate Editor. Dr. Castiglione is a urologist-andrologist and researcher at UCLH-London, UK. He has previously acted as a social media chair for our journal.
Dr. Castiglione obtained his medical degree at Vita-Salute San Raffaele University in 2009. In 2015, he graduated as a urologist and, in 2019, completed a doctorate at KU Leuven (Belgium), studying the possibility of stem cell treatment for penile fibrosis.
Dr. Castiglione has also researched Peyronie’s disease at Lund University in Sweden and Johns Hopkins University in Baltimore, USA. He has written and coauthored over 80 peer-reviewed journal articles and some book chapters. He is an active part of the scientific board of ESSM, member of the YAU (EAU) and ISSM guideline panel.
In a recent Journal of Sexual Medicine study, women who drank alcohol while taking flibanserin did not experience additional adverse events.
Flibanserin is an oral medication intended for premenopausal women with acquired generalized hypoactive sexual desire disorder (HSDD).
The alcohol-interaction study included 96 premenopausal women who took various combinations of flibanserin, a placebo, and ethanol.
The researchers determined that ethanol "did not have an additive effect on the [adverse event] profile of flibanserin."
However, they noted that their study protocol was not a "real-world" scenario, as the participants took flibanserin in the morning, in contrast to the recommended bedtime dosing.
Find out more.